BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...s.r.l. named Mathieu Simon as chairman and Julia Berretta as CEO. Simon is chairman of Lysogene S.A....
BioCentury | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

...DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT); prodrug company Ascendis Pharma A/S (NASDAQ:ASND); CNS-focused gene therapy company Lysogene S.A....
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...Rett syndrome and the University of Florida for cardiomyopathy and multiple sclerosis; a deal with Lysogene S.A....
BioCentury | Apr 18, 2019
Translation in Brief

Blocking phages to prevent wound infections

Stanford researchers have shown that immunizing against a bacteriophage found in Pseudomonas aeruginosa prevented the bacteria from infecting chronic wounds. The findings offering a prophylactic alternative to using antibiotics to treat surgical and other wounds...
BioCentury | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

...in preclinical development: Axovant Sciences Ltd. has AXO-AAV-GM1, an AAV9 vector encoding wild-type GLB1; and Lysogene S.A....
...and Institutions Mentioned Alector Inc., South San Francisco, Calif. Axovant Sciences Ltd. (NASDAQ:AXGT), Basel, Switzerland Lysogene S.A....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....
BioCentury | Oct 19, 2018
Company News

Sarepta gets gene therapy candidate, Lysogene extends runway

...in Lysogene, which is also eligible for up to $125 million in milestones, plus royalties. Lysogene...
...sale of 950,606 shares at $2.63 per share. The price is a 49% premium to Lysogene's...
...SGSH; HNS). Lysogene S.A. (Euronext:LYS), Neuilly-sur-Seine, France Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Endocrine/Metabolic Alicia Parker LYS-SAF302, LYS-SAF-302 Lysogene S.A. Sarepta...
BioCentury | Apr 27, 2018
Company News

Lysogene and others partner to develop gene therapy for Fragile X

...protein responsible for Fragile X syndrome. The partners said first results are expected in 2019. Lysogene S.A....
...Conectus Alsace, Illkirch, France Business: Gene therapy, Neurology Shannon Lehnbeuter Institute of Genetics and Molecular and Cellular Biology Lysogene S.A. Fragile...
BioCentury | Aug 3, 2017
Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
Items per page:
1 - 10 of 32
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...s.r.l. named Mathieu Simon as chairman and Julia Berretta as CEO. Simon is chairman of Lysogene S.A....
BioCentury | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

...DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT); prodrug company Ascendis Pharma A/S (NASDAQ:ASND); CNS-focused gene therapy company Lysogene S.A....
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...Rett syndrome and the University of Florida for cardiomyopathy and multiple sclerosis; a deal with Lysogene S.A....
BioCentury | Apr 18, 2019
Translation in Brief

Blocking phages to prevent wound infections

Stanford researchers have shown that immunizing against a bacteriophage found in Pseudomonas aeruginosa prevented the bacteria from infecting chronic wounds. The findings offering a prophylactic alternative to using antibiotics to treat surgical and other wounds...
BioCentury | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

...in preclinical development: Axovant Sciences Ltd. has AXO-AAV-GM1, an AAV9 vector encoding wild-type GLB1; and Lysogene S.A....
...and Institutions Mentioned Alector Inc., South San Francisco, Calif. Axovant Sciences Ltd. (NASDAQ:AXGT), Basel, Switzerland Lysogene S.A....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...of multiple deals by Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A....
BioCentury | Oct 19, 2018
Company News

Sarepta gets gene therapy candidate, Lysogene extends runway

...in Lysogene, which is also eligible for up to $125 million in milestones, plus royalties. Lysogene...
...sale of 950,606 shares at $2.63 per share. The price is a 49% premium to Lysogene's...
...SGSH; HNS). Lysogene S.A. (Euronext:LYS), Neuilly-sur-Seine, France Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Endocrine/Metabolic Alicia Parker LYS-SAF302, LYS-SAF-302 Lysogene S.A. Sarepta...
BioCentury | Apr 27, 2018
Company News

Lysogene and others partner to develop gene therapy for Fragile X

...protein responsible for Fragile X syndrome. The partners said first results are expected in 2019. Lysogene S.A....
...Conectus Alsace, Illkirch, France Business: Gene therapy, Neurology Shannon Lehnbeuter Institute of Genetics and Molecular and Cellular Biology Lysogene S.A. Fragile...
BioCentury | Aug 3, 2017
Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
Items per page:
1 - 10 of 32